
Biohaven Pharmaceutical Holding Company Ltd. – NYSE:BHVN
Biohaven Pharmaceutical Holding Company Ltd. stock price today
Biohaven Pharmaceutical Holding Company Ltd. stock price monthly change
Biohaven Pharmaceutical Holding Company Ltd. stock price quarterly change
Biohaven Pharmaceutical Holding Company Ltd. stock price yearly change
Biohaven Pharmaceutical Holding Company Ltd. key metrics
Market Cap | 3.61B |
Enterprise value | 613.08M |
P/E | -1.1 |
EV/Sales | 2.85 |
EV/EBITDA | -0.84 |
Price/Sales | 3.66 |
Price/Book | 1.46 |
PEG ratio | N/A |
EPS | -6.83 |
Revenue | N/A |
EBITDA | -537.78M |
Income | -517.18M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -356.25% |
Oper. margin | -291.12% |
Gross margin | 83.38% |
EBIT margin | -291.12% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBiohaven Pharmaceutical Holding Company Ltd. stock price history
Biohaven Pharmaceutical Holding Company Ltd. stock forecast
Biohaven Pharmaceutical Holding Company Ltd. financial statements
$60.6
Potential upside: 291.22%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 0 | -90.34M | |
---|---|---|---|
Sep 2023 | 0 | -102.57M | |
Dec 2023 | 0 | -144.75M | |
Mar 2024 | 0 | -179.50M |
2022-11-09 | -1.30883 | -1.75 |
---|---|---|
2022-12-31 | -7.11094 | -3.78153 |
2023-03-23 | -9.04966 | -3.32 |
Jun 2023 | 506736000 | 119.48M | 23.58% |
---|---|---|---|
Sep 2023 | 382736000 | 92.73M | 24.23% |
Dec 2023 | 513212000 | 85.23M | 16.61% |
Mar 2024 | 418532000 | 117.08M | 27.98% |
Jun 2023 | -44.39M | 76.25M | -20.33M |
---|---|---|---|
Sep 2023 | -94.81M | 58.54M | -39.65M |
Dec 2023 | -114.88M | -3.91M | 210.05M |
Mar 2024 | -102.63M | 34.03M | 3.42M |
Biohaven Pharmaceutical Holding Company Ltd. alternative data
Aug 2023 | 928 |
---|---|
Sep 2023 | 928 |
Oct 2023 | 928 |
Nov 2023 | 928 |
Dec 2023 | 928 |
Jan 2024 | 202 |
Feb 2024 | 202 |
Mar 2024 | 239 |
Apr 2024 | 239 |
May 2024 | 239 |
Jun 2024 | 239 |
Jul 2024 | 239 |
Biohaven Pharmaceutical Holding Company Ltd. other data
Period | Buy | Sel |
---|---|---|
Aug 2023 | 150000 | 0 |
Oct 2023 | 949634 | 0 |
Dec 2023 | 0 | 11000 |
Apr 2024 | 391355 | 0 |
May 2024 | 71500 | 0 |
Jun 2024 | 30000 | 0 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Purchase | CAR BRUCE officer: Chief Sc.. | Common Shares | 30,000 | $33.58 | $1,007,490 | ||
Purchase | CHILDS JOHN W director | Common Shares | 28,000 | $35.58 | $996,240 | ||
Purchase | CHILDS JOHN W director | Common Shares | 28,500 | $35.17 | $1,002,459 | ||
Purchase | BAILEY GREGORY director | Common Shares | 15,000 | $34.19 | $512,880 | ||
Purchase | BAILEY GREGORY director | Common Shares | 25,503 | $39.18 | $999,182 | ||
Purchase | BAILEY GREGORY director | Common Shares | 48,780 | $41 | $1,999,980 | ||
Purchase | CHILDS JOHN W director | Common Shares | 97,560 | $41 | $3,999,960 | ||
Purchase | CHILDS JOHN W director | Common Shares | 73,170 | $41 | $2,999,970 | ||
Purchase | CHILDS JOHN W director | Common Shares | 24,391 | $41 | $1,000,031 | ||
Purchase | CORIC VLAD director, officer: Chief Execut.. | Common Shares | 121,951 | $41 | $4,999,991 |
Patent |
---|
Grant Filling date: 23 Nov 2020 Issue date: 13 Sep 2022 |
Application Filling date: 10 Apr 2020 Issue date: 11 Aug 2022 |
Grant Utility: Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers Filling date: 19 May 2017 Issue date: 2 Aug 2022 |
Application Filling date: 26 May 2019 Issue date: 14 Jul 2022 |
Grant Filling date: 22 Nov 2017 Issue date: 14 Jun 2022 |
Application Filling date: 10 Oct 2019 Issue date: 23 Dec 2021 |
Application Filling date: 19 Jan 2020 Issue date: 4 Nov 2021 |
Grant Filling date: 27 May 2020 Issue date: 10 Aug 2021 |
Application Filling date: 17 Feb 2021 Issue date: 1 Jul 2021 |
Application Filling date: 23 Nov 2020 Issue date: 18 Mar 2021 |
Quarter | Transcript |
---|---|
Q4 2021 25 Feb 2022 | Q4 2021 Earnings Call Transcript |
Q3 2021 9 Nov 2021 | Q3 2021 Earnings Call Transcript |
Q2 2021 9 Aug 2021 | Q2 2021 Earnings Call Transcript |
Q1 2021 10 May 2021 | Q1 2021 Earnings Call Transcript |
Insider | Compensation |
---|---|
Dr. Vladimir Coric M.D. (1971) Chairman, Chief Executive Officer & Pres | $1,260,000 |
Mr. William Jones M.B.A. (1964) Chief Commercial Officer of Migraine & Common Diseases | $931,820 |
Dr. Elyse Stock M.D. (1958) Chief Medical Officer | $726,790 |
Ms. Kimberly Gentile (1966) Senior Vice President of Clinical Operations | $654,990 |
Xenon- A Later Stage Story
Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff
Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge
Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)
argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion
Week In Review: Highlightll Pharma Out-Licenses Parkinson's Treatment To Biohaven For $970 Million
Biohaven: Spun And Done - Time To Exit
Best Macro Pairs Trade Of 2023: Short ARKK And Long Healthcare
Biohaven Stub May Provide An Interesting Setup For Investors
-
What's the price of Biohaven Pharmaceutical Holding Company Ltd. stock today?
One share of Biohaven Pharmaceutical Holding Company Ltd. stock can currently be purchased for approximately $15.49.
-
When is Biohaven Pharmaceutical Holding Company Ltd.'s next earnings date?
Unfortunately, Biohaven Pharmaceutical Holding Company Ltd.'s (BHVN) next earnings date is currently unknown.
-
Does Biohaven Pharmaceutical Holding Company Ltd. pay dividends?
No, Biohaven Pharmaceutical Holding Company Ltd. does not pay dividends.
-
How much money does Biohaven Pharmaceutical Holding Company Ltd. make?
Biohaven Pharmaceutical Holding Company Ltd. has a market capitalization of 3.61B. Biohaven Pharmaceutical Holding Company Ltd. made a loss 408.17M US dollars in net income (profit) last year or -$3.32 on an earnings per share basis.
-
What is Biohaven Pharmaceutical Holding Company Ltd.'s stock symbol?
Biohaven Pharmaceutical Holding Company Ltd. is traded on the NYSE under the ticker symbol "BHVN".
-
What is Biohaven Pharmaceutical Holding Company Ltd.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Biohaven Pharmaceutical Holding Company Ltd.?
Shares of Biohaven Pharmaceutical Holding Company Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Biohaven Pharmaceutical Holding Company Ltd.'s key executives?
Biohaven Pharmaceutical Holding Company Ltd.'s management team includes the following people:
- Dr. Vladimir Coric M.D. Chairman, Chief Executive Officer & Pres(age: 54, pay: $1,260,000)
- Mr. William Jones M.B.A. Chief Commercial Officer of Migraine & Common Diseases(age: 61, pay: $931,820)
- Dr. Elyse Stock M.D. Chief Medical Officer(age: 67, pay: $726,790)
- Ms. Kimberly Gentile Senior Vice President of Clinical Operations(age: 59, pay: $654,990)
-
How many employees does Biohaven Pharmaceutical Holding Company Ltd. have?
As Jul 2024, Biohaven Pharmaceutical Holding Company Ltd. employs 239 workers.
-
When Biohaven Pharmaceutical Holding Company Ltd. went public?
Biohaven Pharmaceutical Holding Company Ltd. is publicly traded company for more then 2 years since IPO on 23 Sep 2022.
-
What is Biohaven Pharmaceutical Holding Company Ltd.'s official website?
The official website for Biohaven Pharmaceutical Holding Company Ltd. is biohavenpharma.com.
-
Where are Biohaven Pharmaceutical Holding Company Ltd.'s headquarters?
Biohaven Pharmaceutical Holding Company Ltd. is headquartered at 215 Church Street, New Haven, CT.
-
How can i contact Biohaven Pharmaceutical Holding Company Ltd.?
Biohaven Pharmaceutical Holding Company Ltd.'s mailing address is 215 Church Street, New Haven, CT and company can be reached via phone at +20 3 4040410.
-
What is Biohaven Pharmaceutical Holding Company Ltd. stock forecast & price target?
Based on 8 Wall Street analysts` predicted price targets for Biohaven Pharmaceutical Holding Company Ltd. in the last 12 months, the avarage price target is $60.6. The average price target represents a 291.22% change from the last price of $15.49.
Biohaven Pharmaceutical Holding Company Ltd. company profile:

Biohaven Pharmaceutical Holding Company Ltd.
biohavenpharma.comNYSE
239
Biotechnology
Healthcare
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
New Haven, CT 06510
CIK: 0001689813
ISIN: VGG1110E1079
CUSIP: G11196105